Ambrx Biopharma Cayman, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax in USD from 2019 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from 2019 to 2022.
  • Ambrx Biopharma Cayman, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending June 30, 2023 was $1.12M, a 13.5% decline year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $7.4M, a 0.71% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $7.46M, a 45.5% decline from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $13.7M, a 32.6% increase from 2019.
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $7.4M -$53K -0.71% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-30
2021 $7.46M -$6.22M -45.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $13.7M +$3.36M +32.6% Jan 1, 2020 Dec 31, 2020 20-F 2022-04-26
2019 $10.3M Jan 1, 2019 Dec 31, 2019 20-F 2022-04-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.